Arimidex vs. Aromasin

[MR10X]

Arimidex can cause negative changes in ones lipid profile, where as Aromasin does not.

Your lipid profile is already ****ed up from doing the cycle in the first place?

[funkymonk]

Your lipid profile is already ****ed up from doing the cycle in the first place?

No reason to add fuel to the fire.

[StickyNicky]

Your lipid profile is already ****ed up from doing the cycle in the first place?

So why would you want to mess it up even further?

[MR10X]

So why would you want to mess it up even further?

All the more reason to not run cycles over 8 to 10 weeks long,you will have messed up lipid levels while on a cycle depending on what your using and shorter cycles sre easier to recover from. HDL levels are decresed with Aromasin

exemestane treatment.

Other Endocrine Effects
Exemestane does not bind significantly to steroidal receptors, except for a slight affinity for the androgen receptor (0.28% relative to dihydrotestosterone). The binding affinity of its 17-dihydrometabolite for the androgen receptor, however, is 100 times that of the parent compound. Daily doses of exemestane up to 25 mg had no significant effect on circulating levels of androstenedione, dehydroepiandrosterone sulfate, or 17-hydroxyprogesterone, and were associated with small decreases in circulating levels of testosterone. Increases in testosterone and androstenedione levels have been observed at daily doses of 200 mg or more. A dose-dependent decrease in sex hormone binding globulin (SHBG) has been observed with daily exemestane doses of 2.5 mg or higher. Slight, nondose-dependent increases in serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels have been observed even at low doses as a consequence of feedback at the pituitary level. Exemestane 25 mg daily had no significant effect on thyroid function [free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH)].

Coagulation and Lipid Effects
In study 027 of postmenopausal women with early breast cancer treated with exemestane (N=73) or placebo (N=73), there was no change in the coagulation parameters activated partial thromboplastin time [APTT], prothrombin time [PT], and fibrinogen. Plasma HDL cholesterol was decreased 6–9% in exemestane treated patients; total cholesterol, LDL cholesterol, triglycerides, apolipoprotein-A1, apolipoprotein-B, and lipoprotein-a were unchanged. An 18% increase in homocysteine levels was also observed in exemestane treated patients compared with a 12% increase seen w